Jun 02, 2020
World Markets for Interferons, 2030 (COVID-19 Adjusted) - Roche, Merck, BMS, Biogen, Bayer, Zydus Cadila, Novartis, Pfizer, Biosidus, and Nanogen are the Major Players
May 27, 2020
Rebif® U.S. Label Now Includes Pregnancy Outcomes and Lactation Information to Help Inform Treatment Decisions for Women with MS
Apr 21, 2020
Multiple Sclerosis Drugs Industry Assessment 2020: Immunomodulators, Immunosuppressants, Interferons and Others
Mar 10, 2020
2020 Disease Analysis: Multiple Sclerosis - Sanofi to Co-Develop Digital Therapeutic for MS Patients
Sep 10, 2019
EMD Serono Initiates Pivotal Phase III Program for Investigational Evobrutinib in Relapsing Multiple Sclerosis
Aug 28, 2019
EMD Serono to Showcase Scientific Leadership at ECTRIMS 2019 with New Data Across Multiple Sclerosis Medicines
May 28, 2019
EMD Serono to Present Data at CMSC Annual Meeting Showcasing Breadth of MS Portfolio and Commitment to Understanding How MS Impacts Patients
Apr 30, 2019
EMD Serono to Present New Data on Mavenclad®, Rebif® and the Investigational Therapy Evobrutinib at the AAN Annual Meeting 2019
Feb 28, 2019
EMD Serono to Present Multiple Sclerosis Data on Cladribine Tablets and Evobrutinib at ACTRIMS 2019
Jan 24, 2019
Global Multiple Sclerosis (MS) Market Insights, Epidemiology and Market Forecasts 2018-2027
Dec 04, 2018
Multiple Sclerosis (MS) Market Analysis, Market size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight
Oct 08, 2018
New Efficacy and Safety Data on MS Portfolio to Be Presented at ECTRIMS 2018
Jul 30, 2018
FDA Accepts File for Cladribine Tablets as Potential Treatment for Relapsing Forms of Multiple Sclerosis
May 29, 2018
EMD Serono to Present MS Data and Debut New Patient Resources at CMSC 2018
May 11, 2018
Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
May 11, 2018
FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients
Apr 13, 2018
EMD Serono Highlights Commitment to Advance Multiple Sclerosis Treatment with Investigational Cladribine Tablets and Rebif® Data at AAN 2018
Mar 21, 2018
Neurodegenerative Diseases Drugs Market, 2023
Feb 26, 2018
Mavenclad (Cladribine Tablets) Receives First Approval in Latin America
Feb 01, 2018
EMD Serono to Present Data Highlighting Investigational Cladribine Tablets at ACTRIMS 2018